EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials

YongSoo Shim iD

Dementia and Neurocognitive Disorders · 2026 · 25 (2) · 130

DOI: 10.12779/dnd.2026.25.2.130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dementia and Neurocognitive Disorders, 2026. Verfasst von YongSoo Shim. Beteiligte Einrichtung: Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

ORCID-Profile: YongSoo Shim

Zitieren

APA

Shim, Y. (2026). Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials. Dementia and Neurocognitive Disorders, 25(2), 130. https://doi.org/10.12779/dnd.2026.25.2.130

Vancouver

Shim Y. Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials. Dementia and Neurocognitive Disorders. 2026;25(2):130. doi:10.12779/dnd.2026.25.2.130

BibTeX
@article{Shim2026,
  author = {Shim, YongSoo},
  title = {Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials},
  journal = {Dementia and Neurocognitive Disorders},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {130},
  doi = {10.12779/dnd.2026.25.2.130}
}
Kostenlos starten →